Master AI-Powered Multi-Omics Data Integration for Biomarker Discovery in 4 weeks through hands-on, project-based online training with DSTC.
Multi-omics data, which includes genomics, transcriptomics, proteomics, and metabolomics, provides a comprehensive view of biological systems but often presents challenges in integration due to the scale and complexity of the data. This course focuses on how AI, particularly machine learning and deep learning, can streamline the integration process, offering new methods for identifying biomarkers. Every participant receives a verified e-Certificate and e-Marksheet from the Deep Science & Technology Consortium.
Multi-omics data, which includes genomics, transcriptomics, proteomics, and metabolomics, provides a comprehensive view of biological systems but often presents challenges in integration due to the scale and complexity of the data. This course focuses on how AI, particularly machine learning and deep learning, can streamline the integration process, offering new methods for identifying biomarkers.
1. Translate biotechnology theory into practical, reproducible analysis.
2. Assemble a documented case study that evidences your applied capability.
β’ Master's and senior undergraduate students specializing in biotechnology
β’ R&D engineers and working professionals applying biotechnology in industry
β’ Academics and educators building research or teaching capacity in biotechnology
β’ A demonstrable biotechnology project for your research or industry portfolio.
β’ A verified e-Certificate of competency and e-Marksheet from the Deep Science & Technology Consortium.
β’ Intended use: diagnostic, prognostic, predictive or monitoring
β’ Cohort design, sample size and the discovery-validation split
β’ Pre-analytical variability as the most common cause of false biomarkers
β’ Early, intermediate and late integration strategies
β’ Multi-omic factor analysis and joint dimensionality reduction
β’ Handling missing modalities across a cohort
β’ Feature selection stability across resamples
β’ Panel size against assay feasibility and cost
β’ Avoiding signatures that encode batch or site rather than biology
β’ Independent cohort validation and prospective design
β’ Analytical validation of the eventual assay, not just the model
β’ Reporting standards and the reasons most published biomarkers fail
β’ Assay transfer from discovery platform to clinical format
β’ Health-economic case and clinical utility evidence
β’ Regulatory pathway for a companion or complementary diagnostic
| Parameter | Requirement |
|---|---|
| Covered Tool / Platform | Python |
| Covered Tool / Platform | TensorFlow |
| Covered Tool / Platform | PyTorch |
| Covered Tool / Platform | Keras |
| Covered Tool / Platform | Scikit-learn |
| Covered Tool / Platform | Jupyter Notebook |
| Covered Tool / Platform | Google Colab |
| Covered Tool / Platform | Hugging Face |
Based on 0 scholar submissions
No verified reviews published yet. Be the first to share your academic experience.
Your rating will help prospective scholars. Ratings below 3 stars are routed privately to the faculty mentor for immediate response.